Pan-TRK Positive Uterine Sarcoma in Immunohistochemistry Without Neurotrophic Tyrosine Receptor Kinase Gene Fusions: A Case Report

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Date 2025 Jan 17

PMID 39823101

Authors

Seungmee Lee

Yu-Ra Jeon

Changmin Shin

Sun-Young Kwon

Sojin Shin

Affiliations

Soon will be listed here.

Abstract

Background: The classification of uterine sarcomas is based on distinctive morphological and immunophenotypic characteristics, increasingly supported by molecular genetic diagnostics. Data on neurotrophic tyrosine receptor kinase () gene fusion-positive uterine sarcoma, potentially aggressive and morphologically similar to fibrosarcoma, are limited due to its recent recognition. Pan-TRK immunohistochemistry (IHC) analysis serves as an effective screening tool with high sensitivity and specificity for -fusion malignancies.

Case Summary: We report a case of a malignant mesenchymal tumor originating from the uterine cervix, which was pan-TRK IHC-positive but lacked gene fusions, accompanied by a brief literature review. A 55-year-old woman presented to the emergency department with abdominal pain and distension, exhibiting significant ascites and multiple solid pelvic masses. Pelvic examination revealed a tumor encompassing the uterine cervix, extending to the vagina and uterine corpus. A punch biopsy of the cervix indicated NTRK sarcoma with positive immunochemical pan-TRK stain. However, subsequent next generation sequencing revealed no gene fusion, leading to a diagnosis of poorly differentiated, advanced-stage sarcoma.

Conclusion: The clinical significance of gene fusion lies in potential treatment with TRK inhibitors for positive sarcomas. Identifying such rare tumors is crucial due to the potential applicability of tropomyosin receptor kinase inhibitor treatment.

References

Wright J, Rosenblum K, Huettner P, Mutch D, Rader J, Powell M . Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol. 2005; 99(2):348-51. DOI: 10.1016/j.ygyno.2005.06.021. View

Solomon J, Hechtman J . Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019; 79(13):3163-3168. PMC: 6606326. DOI: 10.1158/0008-5472.CAN-19-0372. View

Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

Weiss L, Funari V . NTRK fusions and Trk proteins: what are they and how to test for them. Hum Pathol. 2021; 112:59-69. DOI: 10.1016/j.humpath.2021.03.007. View

Drilon A . TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019; 30(Suppl_8):viii23-viii30. PMC: 6859818. DOI: 10.1093/annonc/mdz282. View

Drilon A, Laetsch T, Kummar S, Dubois S, Lassen U, Demetri G . Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8):731-739. PMC: 5857389. DOI: 10.1056/NEJMoa1714448. View

Hughes S, Barbacid M . A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986; 319(6056):743-8. DOI: 10.1038/319743a0. View

Chiang S . S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol. 2020; 40(1):24-27. DOI: 10.1097/PGP.0000000000000702. View

10.

Chiang S, Cotzia P, Hyman D, Drilon A, Tap W, Zhang L . NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Am J Surg Pathol. 2018; 42(6):791-798. PMC: 6764747. DOI: 10.1097/PAS.0000000000001055. View

11.

Demetri G, De Braud F, Drilon A, Siena S, Patel M, Cho B . Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022; 28(7):1302-1312. PMC: 9365368. DOI: 10.1158/1078-0432.CCR-21-3597. View

12.

Church A, Calicchio M, Nardi V, Skalova A, Pinto A, Dillon D . Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2017; 31(3):463-473. DOI: 10.1038/modpathol.2017.127. View

13.

Demetri G, Antonescu C, Bjerkehagen B, Bovee J, Boye K, Chacon M . Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020; 31(11):1506-1517. PMC: 7985805. DOI: 10.1016/j.annonc.2020.08.2232. View

14.

Marino-Enriquez A, Bovee J . Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin. 2016; 9(3):457-73. PMC: 4988391. DOI: 10.1016/j.path.2016.04.009. View

15.

Siozopoulou V, Smits E, De Winne K, Marcq E, Pauwels P . Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel). 2021; 11(3). PMC: 8000177. DOI: 10.3390/diagnostics11030478. View

16.

Suh K, Carlson J, Xia F, Williamson T, Sullivan S . Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic gene fusion cancers. J Comp Eff Res. 2022; 11(14):1011-1019. DOI: 10.2217/cer-2021-0247. View

17.

Hong D, Dubois S, Kummar S, Farago A, Albert C, Rohrberg K . Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020; 21(4):531-540. PMC: 7497841. DOI: 10.1016/S1470-2045(19)30856-3. View